What is AETHLON MEDICAL INC's earnings per share (EPS)?

AETHLON MEDICAL INC (AEMD) reported diluted earnings per share of -$10.61 for fiscal year 2026. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

AETHLON MEDICAL INC (AEMD) Financials

AEMD

FY2026 annual

Net Income -$7.2M +46.6% YoY

EPS (Diluted) -$10.61 YoY not available

Free Cash Flow -$7.0M +8.4% YoY

Operating Cash Flow -$7.0M +8.5% YoY

Market Cap $9.4M as of Oct 12, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2026

Price / Book 1.8x on $5.2M equity, Q1 FY2027

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2027, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE March

Newest figures come from the 10-Q for Q1 FY2027, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AEMD SEC filings page.

This page shows AETHLON MEDICAL INC (AEMD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AEMD FY2026 2026-10-04

Aethlon remains a development-stage business: shrinking operating losses still require recurring financing, while liabilities remain modest relative to assets.

Net loss narrowed to $7.2M by FY2026, but operating cash flow was still -$7.0M, so accounting improvement has not yet produced self-funded operations. Financing cash flow of $6.5M nearly matched that annual outflow, linking the smaller loss to continued dependence on external capital rather than internally generated cash.

R&D exceeded reported revenue in FY2022 and FY2023, while operating cash flow stayed negative through FY2026; this indicates an expense base being carried ahead of dependable commercial scale, rather than a conventional margin story.

Assets contracted from $19.4M in FY2022 to $6.3M in FY2026, while FY2026's current ratio of 3.8x and debt-to-equity ratio of 0.3x show that short-term obligations are not the main balance-sheet pressure. Reported liquidity equaled 8.6 months of the latest annual operating outflow, alongside recurring financing inflows.

Financial Health Signals

Financial health score not available

AETHLON MEDICAL INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

4/6

AETHLON MEDICAL INC passes 4 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

AETHLON MEDICAL INC reported a net loss of $7.2M while operations used $7.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

AETHLON MEDICAL INC reported an operating loss of $7.3M against $14K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$1.5M

YoY+11.9%

AETHLON MEDICAL INC's EBITDA was -$1.5M in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 11.9% from the same quarter a year earlier.

Net Income

-$1.5M

YoY+12.1%

AETHLON MEDICAL INC reported -$1.5M in net income in Q1 2027. This represents an increase of 12.1% from the same quarter a year earlier.

EPS (Diluted)

-$4.02

AETHLON MEDICAL INC earned -$4.02 per diluted share (EPS) in Q1 2027.

Revenue

Not reported for Q1 2027.

Cash & Balance Sheet

Free Cash Flow

-$1.9M

YoY-11.1%

QoQ-8.7%

AETHLON MEDICAL INC recorded an outflow of $1.9M in free cash flow in Q1 2027, representing a cash shortfall after capex. This represents a decrease of 11.1% from the same quarter a year earlier. Against the prior quarter it is down 8.7%.

Cash & Debt

$4.9M

YoY+31.0%

QoQ-1.8%

5Y CAGR-27.8%

10Y CAGR+14.3%

AETHLON MEDICAL INC held $4.9M in cash as of Q1 2027; long-term debt is not reported for that period.

Shares Outstanding

711,136

5Y CAGR-45.9%

10Y CAGR-21.1%

AETHLON MEDICAL INC had 711,136 shares outstanding in Q1 2027.

Dividends Per Share

Not reported for Q1 2027.

Margins & Returns

Return on Equity

-29.8%

YoY+21.7pp

AETHLON MEDICAL INC's ROE was -29.8% in Q1 2027, measuring profit generated per dollar of shareholder equity. This is up 21.7 percentage points from the same quarter a year earlier.

Gross Margin

Not reported for Q1 2027.

Operating Margin

Not reported for Q1 2027.

Net Margin

Not reported for Q1 2027.

Capital Allocation

R&D Spending

$549K

YoY+4.8%

AETHLON MEDICAL INC invested $549K in research and development in Q1 2027. This represents an increase of 4.8% from the same quarter a year earlier.

Capital Expenditures

$9K

QoQ+346.1%

AETHLON MEDICAL INC invested $9K in capex in Q1 2027, funding long-term assets and infrastructure. Against the prior quarter it is up 346.1%.

Share Buybacks

Not reported for Q1 2027.

AEMD Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AEMD quarterly income statement

Metric	TTM	FY26DEF 14A	FY25DEF 14A	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	N/A	N/A	N/A	$0-100.0%	$574K+95.2%	$294K-55.4%	$659K+1.4%	$650K+183.2%	$230K+53.5%	$150K-61.8%	$392K-55.8%	$887K+16.3%	$762K-53.0%	$1.6M+32.0%	$1.2M-9.5%	$1.4M
R&D Expenses	N/A	$1.9M-13.6%	$2.2M-12.2%	$2.5M-8.2%	$2.7M+17.3%	$2.3M+13.0%	$2.1M+123.5%	$927K+3.5%	$896K+52.9%	$586K-12.9%	$673K-13.9%	$782K-23.9%	$1.0M-31.9%	$1.5M+4.8%	$1.4M	N/A
SG&A Expenses	N/A	$2.7M-16.9%	$3.2M-16.9%	$3.9M-12.9%	$4.5M+29.7%	$3.5M+40.6%	$2.5M+58.7%	$1.5M+62.4%	$953K+20.3%	$793K-6.7%	$849K-8.6%	$929K+2.4%	$907K-2.6%	$931K+24.8%	$746K-12.5%	$853K
Operating Income	N/A	-$7.3M+21.9%	-$9.3M+26.1%	-$12.6M-6.2%	-$11.9M-14.2%	-$10.4M-32.1%	-$7.9M-33.1%	-$5.9M+1.2%	-$6.0M-24.2%	-$4.8M+20.8%	-$6.1M-39.1%	-$4.4M-9.8%	-$4.0M-30.7%	-$3.1M+14.5%	-$3.6M-14.8%	-$3.1M
EBITDA	N/A	-$7.0M+22.6%	-$9.0M+26.7%	-$12.3M-5.3%	-$11.7M-13.2%	-$10.3M-31.1%	-$7.9M-33.0%	-$5.9M+1.1%	-$6.0M-24.5%	-$4.8M+20.9%	-$6.1M-39.6%	-$4.3M-9.9%	-$4.0M-30.3%	-$3.0M+14.9%	-$3.6M-15.1%	-$3.1M
Interest Expense	N/A	$14K+42.2%	$10K	N/A	N/A	N/A	$2K-97.1%	$54K-75.4%	$220K-39.0%	$362K+18.8%	$304K+142.2%	$126K-57.8%	$298K-76.8%	$1.3M+213.7%	-$1.1M+70.2%	-$3.8M
Income Tax	N/A	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A
Net Income	N/A	-$7.2M+46.6%	-$13.4M-9.7%	-$12.2M-1.5%	-$12.0M-15.5%	-$10.4M-32.1%	-$7.9M-23.7%	-$6.4M-2.9%	-$6.2M-9.1%	-$5.7M+21.9%	-$7.3M-49.3%	-$4.9M+28.3%	-$6.8M	N/A	-$4.9M	N/A
EPS (Basic)	N/A	-$10.61+87.6%	-$85.77-120.7%	-$38.87-563.3%	-$5.86-725.4%	-$0.71	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$10.61	-$85.77	-$38.87	-$5.86	-$0.71	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	673,945	156,085	314,097	2M	15M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
R&D Expenses	$549K+4.8%	N/A	$533K+121.8%	$294K+12.6%	$524K+26.4%	N/A	$240K-59.5%	$261K-58.4%
SG&A Expenses	$662K-9.9%	N/A	$742K-9.2%	$521K-45.6%	$735K-2.2%	N/A	$816K-16.6%	$958K+12.6%
Operating Income	-$1.6M+11.9%	N/A	-$2.1M-13.6%	-$1.5M+48.0%	-$1.8M+31.6%	N/A	-$1.8M+49.1%	-$2.9M+8.6%
EBITDA	-$1.5M+11.9%	N/A	-$2.0M-14.4%	-$1.4M+49.2%	-$1.7M+32.5%	N/A	-$1.7M+50.2%	-$2.8M+8.7%
Interest Expense	$31K+2.5%	N/A	$44K-26.8%	$23K-76.1%	$31K	N/A	$60K	$95K
Net Income	-$1.5M+12.1%	N/A	-$2.0M-15.0%	-$1.5M+47.0%	-$1.8M+31.5%	N/A	-$1.8M+49.4%	-$2.8M+7.5%
EPS (Basic)	-$4.02+90.5%	$0.40+101.1%	-$2.45+75.6%	-$3.74+76.8%	-$42.42-1437.0%	-$37.42-4012.1%	-$10.05-633.6%	-$16.11-1220.5%
EPS (Diluted)	-$4.02	$0.40+101.1%	-$2.45	-$3.74	-$42.42	-$37.42	-$10.05	-$16.11
Diluted Shares (Avg)	384,705	N/A	823,126	397,513	41,529	N/A	174,529	174,220

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.

AEMD Balance Sheet

AEMD quarterly balance sheet

Metric	FY26DEF 14A	FY25DEF 14A	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$6.3M-13.9%	$7.4M-10.8%	$8.2M-52.9%	$17.5M-9.8%	$19.4M+82.0%	$10.7M+2.7%	$10.4M+151.9%	$4.1M-43.9%	$7.4M+325.9%	$1.7M-31.7%	$2.5M+83.2%	$1.4M-18.6%	$1.7M+241.3%	$497K-40.8%	$839K
Current Assets	$5.6M-6.4%	$5.9M-4.4%	$6.2M-58.7%	$15.1M-16.9%	$18.2M+75.4%	$10.4M+3.1%	$10.0M+148.7%	$4.0M-44.1%	$7.2M+352.7%	$1.6M-32.8%	$2.4M+97.3%	$1.2M-18.6%	$1.5M+305.8%	$365K-47.6%	$696K
Cash & Equivalents	$5.0M-8.6%	$5.5M+1.1%	$5.4M-62.6%	$14.5M-14.9%	$17.1M+73.1%	$9.9M+2.7%	$9.6M+150.9%	$3.8M-45.1%	$7.0M+347.1%	$1.6M-26.6%	$2.1M+148.2%	$856K-31.6%	$1.3M+898.0%	$125K-12.9%	$144K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	N/A	N/A	N/A	$0-100.0%	$128K-14.2%	$149K-27.9%	$207K	$0-100.0%	$75K	$0-100.0%	$199K+3.2%	$193K+103.1%	$95K-54.4%	$209K-47.8%	$400K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$1.4M-35.3%	$2.2M-9.8%	$2.5M+1.4%	$2.4M+0.7%	$2.4M+76.4%	$1.4M+23.9%	$1.1M-39.1%	$1.8M+38.3%	$1.3M+16.6%	$1.1M+10.1%	$1.0M+40.8%	$729K-95.6%	$16.4M+70.4%	$9.6M-4.9%	$10.1M
Current Liabilities	$1.4M-23.8%	$1.9M+3.8%	$1.8M+21.6%	$1.5M-17.5%	$1.8M+32.6%	$1.4M+28.8%	$1.1M-41.5%	$1.8M+281.6%	$478K-21.9%	$612K+16.2%	$527K-8.3%	$574K-96.3%	$15.6M+62.3%	$9.6M-4.9%	$10.1M
Non-Current Liabilities	$0-100.0%	$337K-48.2%	$650K-30.9%	$940K+56.0%	$603K	$0-100.0%	$43K	$0-100.0%	$841K+62.0%	$519K+3.8%	$500K+222.2%	$155K-80.0%	$776K	$0	$0
Total Equity	$4.9M-4.6%	$5.1M-11.1%	$5.8M-61.7%	$15.1M-11.3%	$17.0M+80.2%	$9.4M+0.2%	$9.4M+288.0%	$2.4M-60.5%	$6.1M+806.9%	$676K-56.4%	$1.6M+152.3%	$615K+104.1%	-$14.9M-63.5%	-$9.1M+1.6%	-$9.3M
Retained Earnings	-$175.1M-4.3%	-$168.0M-8.7%	-$154.6M-8.6%	-$142.4M-9.2%	-$130.3M-8.7%	-$119.9M-7.0%	-$112.0M-6.0%	-$105.7M-6.2%	-$99.5M-6.1%	-$93.8M-8.4%	-$86.5M-6.0%	-$81.6M-9.1%	-$74.8M-21.7%	-$61.5M-8.6%	-$56.6M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Total Assets	$6.2M+17.5%	$6.3M-13.9%	$8.1M+23.5%	$7.3M-17.2%	$5.3M-53.5%	$7.4M-10.8%	$6.5M-37.5%	$8.8M-31.0%
Current Assets	$5.6M+38.5%	$5.6M-6.4%	$7.1M+43.7%	$6.3M-12.4%	$4.1M-57.6%	$5.9M-4.4%	$5.0M-39.8%	$7.1M-31.9%
Cash & Equivalents	$4.9M+31.0%	$5.0M-8.6%	$7.0M+44.2%	$5.9M-14.7%	$3.8M-58.5%	$5.5M+1.1%	$4.8M-39.5%	$6.9M-32.6%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$1.0M-45.0%	$1.4M-35.3%	$1.3M-38.7%	$1.6M-44.2%	$1.9M-30.4%	$2.2M-9.8%	$2.2M-22.4%	$2.8M+12.7%
Current Liabilities	$1.0M-36.3%	$1.4M-23.8%	$1.3M-29.1%	$1.4M-39.7%	$1.6M-23.6%	$1.9M+3.8%	$1.8M-15.6%	$2.3M+36.3%
Non-Current Liabilities	$0-100.0%	$0-100.0%	$87K-79.2%	$172K-65.4%	$255K-55.6%	$337K-48.2%	$418K-42.4%	$497K-37.8%
Total Equity	$5.2M+51.9%	$4.9M-4.6%	$6.7M+54.9%	$5.7M-4.5%	$3.4M-60.7%	$5.1M-11.1%	$4.3M-43.1%	$6.0M-41.7%
Retained Earnings	-$176.7M-4.1%	-$175.1M-4.3%	-$173.2M-7.1%	-$171.2M-7.0%	-$169.7M-8.0%	-$168.0M-8.7%	-$161.7M-6.3%	-$159.9M-7.6%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

AEMD Cash Flow Statement

AEMD quarterly cash flow statement

Metric	TTM	FY26DEF 14A	FY25DEF 14A	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	-$7.2M	-$7.0M+8.5%	-$7.6M+24.5%	-$10.1M+3.6%	-$10.5M-7.6%	-$9.8M-44.4%	-$6.8M-30.2%	-$5.2M-21.1%	-$4.3M-9.8%	-$3.9M-11.5%	-$3.5M+19.0%	-$4.3M+14.3%	-$5.0M-136.1%	-$2.1M-1.9%	-$2.1M-14.0%	-$1.8M
Depreciation & Amortization	N/A	$324K-4.7%	$340K-5.4%	$359K+49.1%	$241K+94.8%	$124K+209.7%	$40K+51.5%	$26K-14.1%	$31K-13.9%	$36K+10.0%	$32K-15.9%	$39K+3.1%	$37K+77.1%	$21K+101.1%	$10K-39.1%	$17K
Stock-Based Compensation	N/A	$279K-32.9%	$415K-65.9%	$1.2M+15.9%	$1.1M+40.1%	$751K-3.7%	$779K-7.7%	$844K-36.0%	$1.3M+4.6%	$1.3M-42.3%	$2.2M+977.8%	$203K-51.3%	$416K-31.5%	$608K-20.6%	$765K+0.8%	$759K
Capital Expenditures	N/A	$4K	$0-100.0%	$251K-73.4%	$943K+170.1%	$349K+483.1%	$60K-60.5%	$152K	$0-100.0%	$25K+51.1%	$16K+76.6%	$9K	$0-100.0%	$96K	$0-100.0%	$2K
Free Cash Flow	N/A	-$7.0M+8.4%	-$7.6M+26.3%	-$10.4M+9.3%	-$11.4M-13.2%	-$10.1M-48.2%	-$6.8M-27.6%	-$5.3M-24.6%	-$4.3M-9.1%	-$3.9M-11.7%	-$3.5M+18.8%	-$4.3M+14.1%	-$5.0M-125.9%	-$2.2M-6.5%	-$2.1M-13.9%	-$1.8M
Investing Cash Flow	N/A	-$4K	$0+100.0%	-$251K+73.4%	-$943K-170.1%	-$349K-483.1%	-$60K+60.5%	-$152K	$0+100.0%	-$25K-51.1%	-$16K-76.6%	-$9K	$0+100.0%	-$96K	$0+100.0%	-$2K
Financing Cash Flow	$8.3M	$6.5M-15.6%	$7.7M+500.1%	$1.3M-85.6%	$8.9M-48.7%	$17.4M+143.6%	$7.1M-35.9%	$11.1M+869.6%	$1.1M-87.7%	$9.3M+216.1%	$3.0M-47.2%	$5.6M+20.5%	$4.7M+38.5%	$3.4M+61.5%	$2.1M+5.5%	$2.0M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$194K-30.4%	$279K-26.4%	$379K	$0	N/A	N/A	N/A	N/A

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Operating Cash Flow	-$1.9M-10.6%	-$1.8M-4.6%	-$1.9M+6.8%	-$1.7M+25.1%	-$1.7M+1.9%	-$1.7M+34.8%	-$2.0M+15.4%	-$2.2M+18.1%
Depreciation & Amortization	$73K-11.8%	$80K-5.1%	$82K-2.6%	$80K-6.9%	$83K-4.0%	$84K-2.3%	$84K-8.4%	$86K-6.1%
Stock-Based Compensation	$50K-31.0%	N/A	$72K-19.5%	$72K-36.2%	$72K-48.0%	N/A	$90K-84.3%	$113K-55.9%
Capital Expenditures	$9K	$2K-6.4%	N/A	N/A	$0	-$2K-55.3%	$2K-75.1%	$0-100.0%
Free Cash Flow	-$1.9M-11.1%	-$1.8M-4.6%	N/A	N/A	-$1.7M+1.9%	-$1.7M+34.8%	-$2.0M+15.7%	-$2.2M+18.3%
Investing Cash Flow	-$9K	-$2K-193.6%	N/A	N/A	$0	$2K+144.7%	-$2K+75.1%	$0+100.0%
Financing Cash Flow	$1.8M+34021.1%	-$196K-108.3%	$3.0M+42269.3%	$3.7M+97728.4%	-$5K-100.1%	$2.4M+5441.3%	-$7K-104.0%	-$4K+61.1%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

AEMD Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AEMD quarterly financial ratios

Metric	FY26DEF 14A	FY25DEF 14A	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Margin	N/A	N/A	N/A	-2072.1%	-3542.5%	-1197.3%	-912.0%	-2612.5%	-3228.8%	-1555.4%	-494.6%	-523.7%	-188.2%	-290.7%	-229.1%
Net Margin	N/A	N/A	N/A	-2094.9%	-3540.9%	-1196.6%	-980.3%	-2697.8%	-3795.9%	-1855.8%	-549.6%	-891.5%	N/A	-397.7%	N/A
Return on Equity	-146.3%+115.2pp	-261.5%-49.8pp	-211.8%-131.9pp	-79.9%-18.6pp	-61.3%+22.3pp	-83.6%-15.9pp	-67.7%+187.7pp	-255.4%-162.8pp	-92.6%+983.1pp	-1075.7%-762.0pp	-313.8%+790.6pp	-1104.4%	N/A	N/A	N/A
Return on Assets	-112.9%+69.2pp	-182.1%-34.0pp	-148.1%-79.4pp	-68.7%-15.1pp	-53.6%+20.3pp	-73.9%-12.6pp	-61.4%+88.9pp	-150.3%-73.0pp	-77.3%+344.2pp	-421.5%-228.8pp	-192.7%+299.7pp	-492.3%	N/A	-984.9%	N/A
Current Ratio	3.85+0.7x	3.13-0.3x	3.40-6.6x	10.03+0.1x	9.95+2.4x	7.53-1.9x	9.40+7.2x	2.21-12.9x	15.13+12.5x	2.61-1.9x	4.51+2.4x	2.10+2.0x	0.09+0.1x	0.040.0x	0.07
Debt-to-Equity	0.30-0.1x	0.440.0x	0.43+0.3x	0.160.0x	0.140.0x	0.150.0x	0.12-0.6x	0.75+0.5x	0.21-1.5x	1.67+1.0x	0.66-0.5x	1.18	N/A	N/A	N/A
Asset Turnover	N/A	N/A	0.000.0x	0.030.0x	0.020.0x	0.060.0x	0.060.0x	0.060.0x	0.02-0.2x	0.23-0.1x	0.35-0.2x	0.55-0.4x	0.96-1.5x	2.48+0.9x	1.62
FCF Margin	N/A	N/A	N/A	-1993.6%	-3439.0%	-1035.5%	-822.7%	-1869.8%	-2630.2%	-898.4%	-489.4%	-662.3%	-137.6%	-170.6%	-135.6%

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Return on Equity	-29.8%+21.7pp	N/A	-30.1%+10.4pp	-25.9%+20.8pp	-51.5%-21.9pp	N/A	-40.5%+5.1pp	-46.6%-17.2pp
Return on Assets	-24.8%+8.4pp	N/A	-25.1%+1.8pp	-20.3%+11.4pp	-33.2%-10.7pp	N/A	-26.9%+6.3pp	-31.7%-8.1pp
Current Ratio	5.42+2.9x	3.85+0.7x	5.68+2.9x	4.45+1.4x	2.49-2.0x	3.13-0.3x	2.80-1.1x	3.06-3.1x
Debt-to-Equity	0.20-0.4x	0.30-0.1x	0.20-0.3x	0.27-0.2x	0.55+0.2x	0.440.0x	0.51+0.1x	0.47+0.2x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
AETHLON MEDICAL INC AEMD	FY2026	N/A	-$7.2M	N/A	$9.4M	—
Bluejay Diagnostics, Inc. BJDX	FY2025	N/A	-$6.8M	N/A	$853K	—
Catheter Precision, Inc. VTAK	FY2025	$819K	-$17.2M	N/A	$549K	—
Nuwellis, Inc. NUWE	FY2025	$8.3M	-$17.5M	N/A	$2.2M	46/100
Bone Biologics Corp BBLG	FY2025	N/A	-$3.1M	N/A	$1.3M	—
Autonomix Medical, Inc. AMIX	FY2026	$0	-$16.7M	N/A	$6.1M	—

Where AETHLON MEDICAL INC Ranks

Frequently Asked Questions

Is AETHLON MEDICAL INC profitable?

No, AETHLON MEDICAL INC (AEMD) reported a net income of -$7.2M in fiscal year 2026.

What is AETHLON MEDICAL INC's EBITDA?

AETHLON MEDICAL INC (AEMD) had EBITDA of -$7.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

What is AETHLON MEDICAL INC's return on equity (ROE)?

AETHLON MEDICAL INC (AEMD) has a return on equity of -146.3% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is AETHLON MEDICAL INC's free cash flow?

AETHLON MEDICAL INC (AEMD) recorded an outflow of $7.0M in free cash flow during fiscal year 2026. This represents a 8.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is AETHLON MEDICAL INC's operating cash flow?

AETHLON MEDICAL INC (AEMD) recorded an outflow of $7.0M in operating cash flow during fiscal year 2026, representing cash used by core business activities.

What are AETHLON MEDICAL INC's total assets?

AETHLON MEDICAL INC (AEMD) had $6.3M in total assets as of fiscal year 2026, including both current and long-term assets.

What are AETHLON MEDICAL INC's capital expenditures?

AETHLON MEDICAL INC (AEMD) invested $4K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How much does AETHLON MEDICAL INC spend on research and development?

AETHLON MEDICAL INC (AEMD) invested $1.9M in research and development during fiscal year 2026.

How many shares does AETHLON MEDICAL INC have outstanding?

AETHLON MEDICAL INC (AEMD) had 2M shares outstanding as of fiscal year 2026.

What is AETHLON MEDICAL INC's current ratio?

AETHLON MEDICAL INC (AEMD) had a current ratio of 3.85 as of fiscal year 2026, which is generally considered healthy.

What is AETHLON MEDICAL INC's debt-to-equity ratio?

AETHLON MEDICAL INC (AEMD) had a debt-to-equity ratio of 0.30 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is AETHLON MEDICAL INC's return on assets (ROA)?

AETHLON MEDICAL INC (AEMD) had a return on assets of -112.9% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is AETHLON MEDICAL INC's P/E ratio?

AETHLON MEDICAL INC (AEMD) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $9.4M as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is AETHLON MEDICAL INC's price-to-sales ratio?

AETHLON MEDICAL INC (AEMD) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $9.4M as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does AETHLON MEDICAL INC's liquidity compare with its operating cash outflow?

At the end of fiscal year 2026, AETHLON MEDICAL INC (AEMD) held $5.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $7.0M over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is AETHLON MEDICAL INC's Piotroski F-Score?

AETHLON MEDICAL INC (AEMD) has a Piotroski F-Score of 4 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are AETHLON MEDICAL INC's earnings high quality?

AETHLON MEDICAL INC (AEMD) reported a net loss of $7.2M while operations used $7.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can AETHLON MEDICAL INC cover its interest payments?

AETHLON MEDICAL INC (AEMD) reported an operating loss of $7.3M against $14K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.